Tests patients' own bone marrow cells for certain nerve and brain conditions
Tests own bone marrow cells in adults with nerve or brain conditions.
Key facts
- Who runs it
- MD Stem Cells
- Where
- Dubai, United Arab EmiratesSee the siteAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Neurologic Stem Cell Treatment Study
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- Jun 2016
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional
- Treatments tested
- Intravenous and Intranasal BMSC
- Record updated
- 26 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lasting damage to the nervous system who are unlikely to improve with standard care. It tests bone marrow stem cells given through a vein and the nose.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Documented functional damage to the central or peripheral nervous system, at least 6 months after the disease began, unlikely to improve with present standard of care.
- Earlier treatment
- People already on medical therapy (medicine or surgery) must be stable on it. The ongoing treatment must be unlikely to reverse the nerve damage.
Main reasons for not taking part
- Cannot have a neurologic exam or cannot cooperate with it
- Cannot or will not attend follow-up neurologic exams
- Cannot give informed consent
- Not medically stable, or at significant health risk from the procedure
- Pregnant at the time of treatment
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care
- Be at least 6 months post-onset of the disease
- If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment
- In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure
- Be over the age of 18 and capable of providing informed consent
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health
Who cannot take part
- Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment
- All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam
- Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol
- Patients must be capable of providing informed consent
- In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function.
- Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible
Where in United Arab Emirates
Also in 1 other country, 2 sites
- The Saudi-German HospitalDubai, United Arab EmiratesContact: Steven Levy, MDTaking people
About the trial
What the trial wants to find out
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
The group in the trial
- Arm 1- Intravenous and Intranasal BMSCOther group
Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
Treatment: Intravenous and Intranasal BMSC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neurologic Bone Marrow Derived Stem Cell Treatment Study
- Plain-language title
- Tests patients' own bone marrow cells for certain nerve and brain conditionsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 June 2026